IVIEW Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for ocular diseases. By focusing on unmet medical needs in the ophthalmology sector, the company aims to create effective therapies for conditions including dry eye disease, conjunctivitis, myopia, glaucoma, and presbyopia.
IVW-1001 is a novel TRPM8 agonist specifically designed for the treatment of dry eye disease. This innovative product is delivered via an ophthalmic eyelid wipe, ensuring both ease of use and targeted action directly at the affected area.
IVW-1001 addresses the significant quality of life issues faced by patients suffering from dry eye disease, providing a differentiated treatment option with its innovative delivery method.
The company addresses critical patient needs for effective and accessible treatment options for debilitating ocular diseases.